319 Method of stratification for proximal colorectal cancer patients

Asset Overview

Product Type	method of stratification (Antibody)
Indication	Oncology
Current Stage	Lead Identification/optimization
Target(MoA)	Anti-IL-22 mAb
Brief Description	Oxford researchers have indentified a proximal, IL22RA1^{high}, KRAS mutant molecular CRC subtype.
Organization	Oxford University

Differentiation

□ **Personalised Medicine**

- In patients with colorectal cancer (CRC) the location and genetic profile of the tumour drastically affects their prognosis. Accurate characterisation of these tumours through biomarker analysis allows for the administration of more personalised therapies. For this to be possible, new methods are required to differentiate these CRC subtypes.

□ **Molecular Stratification**

- Oxford researchers have identified a proximal, **IL22RA1^{high,} KRAS mutant molecular CRC subtype**. The presence of these biomarkers dramatically worsens the prognosis for patients with proximal CRC. In **KRAS mutant tumours, IL-22 promotes both chemoresistance and clonogenic outgrowth**. Due to this, the group proposes an alternative CRC treatment based on anti- IL-22 monoclonal antibody therapy.

□ **The benefits of this molecular stratification include :**

- Identification of CRC subtype with poor prognosis
- Allows adaptation of the treatment administered
- New avenues for treatment of the CRC subtype

319 Method of stratification for proximal colorectal cancer patients

Key Data

Cytokines in the pathogenesis of colorectal cancer



Phenotype of IL22RA1high, KRAS mutant in CRC



319 Method of stratification for proximal colorectal cancer patients

Intellectual Property

Patent No.	PCT-GB2016-051466
Application Date	2016.05.20
Status	Application Pending
Country	US, EP

Contact Information

Contact Person	Dr. Richard Reschen
Email	richard.reschen@innovation.ox.ac.uk
URL	